Umbilical mesenchymal stem cells mitigate T-cell compartments shift and Th17/Treg imbalance in acute ischemic stroke via mitochondrial transfer
- PMID: 40075467
- PMCID: PMC11905603
- DOI: 10.1186/s13287-025-04224-6
Umbilical mesenchymal stem cells mitigate T-cell compartments shift and Th17/Treg imbalance in acute ischemic stroke via mitochondrial transfer
Abstract
Background: Acute ischemic stroke (AIS) initiates secondary injuries that worsen neurological damage and hinder recovery. While peripheral immune responses play a key role in stroke outcomes, clinical results from immunotherapy have been suboptimal, with limited focus on T-cell dynamics. Umbilical mesenchymal stem cells (UMSCs) offer therapeutic potential due to their immunomodulatory properties. They can regulate immune responses and reduce neuroinflammation, potentially enhancing recovery by fostering a pro-regenerative peripheral immune environment. However, the effect of UMSCs on T-cell dynamics in AIS remains underexplored. This study investigates T-cell dynamics following AIS and examines how UMSCs may mitigate immune dysregulation to develop better treatment strategies.
Methods: AIS patients (NIHSS scores 0-15) were recruited within 72 h of stroke onset, with peripheral blood samples collected on Day 0 (enrollment) and Day 7. T-cell compartments were identified by flow cytometry, and plasma cytokine levels were quantified using a cytometric bead array (CBA). Mitochondria in UMSCs were labeled with MitoTracker. Peripheral blood mononuclear cells from patients were isolated, treated with lipopolysaccharide (LPS), and cocultured with UMSCs in both direct contact and Transwell systems. Flow cytometry, CBA, RT-qPCR, and immunofluorescence assays were used to detect T-cell compartments, gene expression markers for helper T (Th) cell differentiation, cytokine profiles, mitochondrial transfer, reactive oxygen species (ROS) production, and mitochondrial membrane potential. Additionally, mitochondrial DNA in UMSCs was depleted. The effects of UMSCs and mitochondria-depleted UMSCs on ischemic stroke mice were compared through behavioral assessments and analysis of the peripheral immune microenvironment.
Results: In AIS, T-cell compartments underwent a phenotypic shift from naïve to effector or memory states, with a specific increase in Th17 cells and a decrease in regulatory T cells, leading to alterations in T-cell-mediated immune functions. In an ex vivo co-culture system, LPS stimulation further amplified these disparities, inducing mitochondrial dysfunction and oxidative stress in T cells. Notably, UMSCs restored mitochondrial function and reversed the shift in T-cell compartments through mitochondrial transfer. Critically, UMSC treatment significantly improved both neurological deficits and peripheral immune disorders in ischemic stroke mice, whereas mitochondria-depleted UMSCs failed to produce this effect.
Conclusions: Our comprehensive insights into the key attributes of T-cell compartments in acute ischemic stroke and the immune regulatory mechanisms of UMSCs provide a crucial theoretical foundation for understanding peripheral immune disorders in ischemic stroke and the therapeutic potential of UMSC treatment.
Keywords: Acute ischemic stroke; Mitochondrial transfer; T-cell compartment; Th17/Treg imbalance; Umbilical mesenchymal stem cells.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was conducted at the Stem Cell Clinical Research Center of the First Affiliated Hospital of Dalian Medical University. The study, titled "Clinical Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Acute Ischemic Stroke" (No. YJ-GXB-2022-01, January 16, 2022), received ethical approval from the Ethics Committee of the First Affiliated Hospital of Dalian Medical University. The approval encompassed the isolation and preparation of human umbilical cord mesenchymal stem cells, the recruitment of patients with acute ischemic stroke, and the collection of their biological samples for research purposes. Written informed consent was obtained from all patients or their legally authorized representatives. The animal studies were approved by the Ethics Committee of the Animal Experiment Center of Dalian Medical University and conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The approved project was titled "Investigation of the Effects of Stem Cells and Engineered Vesicles on Neurological Repair in Ischemic Stroke" (No. AEE23127, February 28, 2023). In addition, this work has been reported in line with the ARRIVE guidelines 2.0. There were no ethical conflicts associated with this manuscript. Consent for publication: Not applicable. Artificial intelligence (AI): The authors declare that they have not use AI-generated work in this manuscript" in this section. Competing interests: The authors declare that they have no competing interests.
Figures







References
MeSH terms
Grants and funding
- 2022RG18/Dalian Science and Technology Talent Innovation Support Policy Implementation Plan High-level Talent Team
- [2021]49/Liaoning Province Science and Technology Plan Orientation Project
- 2021RQ028/Dalian high-level talent innovation support plan
- 2022-BS-238/Liaoning Province Natural Science Foundation project
LinkOut - more resources
Full Text Sources
Medical